Latest ROE for Elekta AB Class B: -10.2% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-10.20%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Elekta AB Class B (EKTAF) currently reports a ROE of -10.2%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Elekta AB Class B's ROE history and peer comparisons.
Elekta AB Class B's ROE of -10.2% is lower than the Healthcare sector average of 29.33%. That is roughly 134.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Elekta AB Class B's current -10.2% should be judged against Healthcare norms (sector average: 29.33%) and against EKTAF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -10.2%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Elekta AB Class B, and consider following EKTAF for alerts when major investors trade the stock.
Elekta AB Class B is classified in the Healthcare sector. On ROE, it currently shows -10.2% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EKTAF with unrelated industries.